207 related articles for article (PubMed ID: 21475141)
1. Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.
Ward SJ; Raffa RB
Obesity (Silver Spring); 2011 Jul; 19(7):1325-34. PubMed ID: 21475141
[No Abstract] [Full Text] [Related]
2. Antagonism of type-1 cannabinoid receptors: good for obesity, but is it safe for fertility?
Maccarrone M; Wang H; Dey SK
Clin Endocrinol (Oxf); 2007 Mar; 66(3):456-7. PubMed ID: 17302885
[No Abstract] [Full Text] [Related]
3. End of the line for cannabinoid receptor 1 as an anti-obesity target?
Jones D
Nat Rev Drug Discov; 2008 Dec; 7(12):961-2. PubMed ID: 19043439
[TBL] [Abstract][Full Text] [Related]
4. Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study.
Warren KR; Buchanan RW; Feldman S; Conley RR; Linthicum J; Ball MP; Liu F; McMahon RP; Gorelick DA; Huestis MA; Kelly DL
J Clin Psychopharmacol; 2013 Feb; 33(1):118-20. PubMed ID: 23277241
[No Abstract] [Full Text] [Related]
5. How inverse can a neutral antagonist be? Strategic questions after the rimonabant issue.
Giraldo J
Drug Discov Today; 2010 Jun; 15(11-12):411-5. PubMed ID: 20447467
[TBL] [Abstract][Full Text] [Related]
6. The safety of obesity drugs.
Van Gaal LF; Scheen AJ; Formiguera X
Expert Opin Drug Saf; 2007 Sep; 6(5):475-6; author reply 477-8. PubMed ID: 17877434
[No Abstract] [Full Text] [Related]
7. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
[TBL] [Abstract][Full Text] [Related]
8. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].
Ducobu J; Sternon J
J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid receptor CB1 antagonists state of the art and challenges.
Bifulco M; Santoro A; Laezza C; Malfitano AM
Vitam Horm; 2009; 81():159-89. PubMed ID: 19647112
[TBL] [Abstract][Full Text] [Related]
10. [Endocannabinoids: therapeutic perspectives in chronic liver diseases].
Lotersztajn S; Teixeira-Clerc F; Hezode C; Tran van Nhieu J; Deveaux V; Mallat A
Gastroenterol Clin Biol; 2007 Mar; 31(3):255-8. PubMed ID: 17396081
[No Abstract] [Full Text] [Related]
11. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders.
Silvestri C; Di Marzo V
Expert Opin Investig Drugs; 2012 Sep; 21(9):1309-22. PubMed ID: 22780328
[TBL] [Abstract][Full Text] [Related]
12. Rehashing endocannabinoid antagonists: can we selectively target the periphery to safely treat obesity and type 2 diabetes?
Patti ME
J Clin Invest; 2010 Aug; 120(8):2646-8. PubMed ID: 20664166
[TBL] [Abstract][Full Text] [Related]
13. Metabolic syndrome treatment strategies.
Fujioka K
Pharmacotherapy; 2006 Dec; 26(12 Pt 2):222S-226S. PubMed ID: 17125449
[TBL] [Abstract][Full Text] [Related]
14. CB1 cannabinoid receptor inhibition: promising approach for heart failure?
Mukhopadhyay P; Mohanraj R; Bátkai S; Pacher P
Congest Heart Fail; 2008; 14(6):330-4. PubMed ID: 19076859
[No Abstract] [Full Text] [Related]
15. Differential effects of cannabinoid CB1 inverse agonists and antagonists on impulsivity in male Sprague Dawley rats: identification of a possibly clinically relevant vulnerability involving the serotonin 5HT
McLaughlin PJ; Jagielo-Miller JE; Plyler ES; Schutte KK; Vemuri VK; Makriyannis A
Psychopharmacology (Berl); 2017 Mar; 234(6):1029-1043. PubMed ID: 28144708
[TBL] [Abstract][Full Text] [Related]
16. The psychiatric side-effects of rimonabant.
Moreira FA; Crippa JA
Braz J Psychiatry; 2009 Jun; 31(2):145-53. PubMed ID: 19578688
[TBL] [Abstract][Full Text] [Related]
17. Rimonabant and progression of atherosclerosis in obese persons.
Dora JM; Scheffel RS
JAMA; 2008 Jul; 300(3):280; author reply 280-1. PubMed ID: 18632538
[No Abstract] [Full Text] [Related]
18. Rimonabant: suicide and depression. Depression and suicidal tendencies are about twice as frequent with rimonabant as with placebo.
Prescrire Int; 2007 Dec; 16(92):250. PubMed ID: 18092422
[No Abstract] [Full Text] [Related]
19. [The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].
Boekholdt SM; Jukema JW; Peters RJ
Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2615-9. PubMed ID: 18161262
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of targeting the endocannabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation.
Tucci SA; Halford JC; Harrold JA; Kirkham TC
Curr Med Chem; 2006; 13(22):2669-80. PubMed ID: 17017918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
